Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma

This publication has 14 references indexed in Scilit:

• Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
  Blood Cancer Journal, 2016
• Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
  The Lancet Oncology, 2016
• Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
  New England Journal of Medicine, 2015
• Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring
  BMC Cancer, 2014
• Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)
  Blood, 2013
• Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
  Haematologica, 2013
• Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
  Current Cardiology Reviews, 2012
• Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
  Cancer Research, 2007
• Risk Factors for Congestive Heart Failure in US Men and Women
  Archives of internal medicine (1960), 2001
• Serial Assessment of Doxorubicin Cardiotoxicity with Quantitative Radionuclide Angiocardiography
  New England Journal of Medicine, 1979